Skip to main content
Erschienen in:

13.07.2017

The Assessment of Cough in a Sarcoidosis Clinic Using a Validated instrument and a Visual Analog Scale

verfasst von: Marc A. Judson, Amit Chopra, Edward Conuel, Efstratios Koutroumpakis, Christopher Schafer, Adam Austin, Robert Zhang, Kerry Cao, Rani Berry, Malik M. H. S. Khan, Aakash Modi, Ritu Modi, Stephanie Jou, Furqan Ilyas, Recai M. Yucel

Erschienen in: Lung | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cough is a common symptom of pulmonary sarcoidosis. We analyzed the severity of cough and factors associated with cough in a university sarcoidosis clinic cohort.

Methods

Consecutive patients completed the Leicester Cough Questionnaire (LCQ) and a cough visual analog scale (VAS). Clinical and demographic data were collected. Means of the LCQ were analyzed in patients who had multiple visits in terms of constant variables (e.g., race, sex).

Results

355 patients completed the LCQ and VAS at 874 visits. Cough was significantly worse in blacks than whites as determined by the LCQ-mean (16.5 ± 2.6 vs. 17.8 ± 3.0, p < 0.001) and VAS-mean (3.8 ± 3.0 vs. 2.0 ± 2.6, p < 0.0001). Cough was worse in women than men as measured by the VAS-mean (2.7 ± 2.9 vs. 2.2 ± 2.7, p = 0.002), one of the LCQ-mean domains (LCQ-Social-mean 5.4 ± 0.9 vs. 5.2 ± 1.0, p = 0.03), but not the total LCQ-mean score. Cough was not significantly different by either measure in terms of smoking status, age, or spirometric parameter (FVC % predicted, FEV1 % predicted, FEV1/FVC). In a multivariable linear regression analysis, cough was significantly worse in blacks than whites and in pulmonary sarcoidosis than non-pulmonary sarcoidosis with both cough measures, in women than men for the VAS only, and not for spirometric parameters, Scadding stage, or age. The LCQ and VAS were strongly correlated.

Conclusions

In a large university outpatient sarcoidosis cohort, cough was worse in blacks than whites. Cough was not statistically significantly different in terms of age, spirometric measures, Scadding stage, or smoking status. The LCQ correlated strongly with a visual analog scale for cough.
Literatur
3.
Zurück zum Zitat McKinzie BP, Bullington WM, Mazur JE, Judson MA (2010) Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations. Am J Med Sci 339(1):1–4CrossRefPubMed McKinzie BP, Bullington WM, Mazur JE, Judson MA (2010) Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations. Am J Med Sci 339(1):1–4CrossRefPubMed
4.
Zurück zum Zitat Birring SS, Spinou A (2015) How best to measure cough clinically. Curr Opin Pharmacol 22:37–40CrossRefPubMed Birring SS, Spinou A (2015) How best to measure cough clinically. Curr Opin Pharmacol 22:37–40CrossRefPubMed
5.
Zurück zum Zitat Birring SS, Fleming T, Matos S, Raj AA, Evans DH, Pavord ID (2008) The Leicester Cough Monitor: preliminary validation of an automated cough detection system in chronic cough. Eur Respir J 31(5):1013–1018CrossRefPubMed Birring SS, Fleming T, Matos S, Raj AA, Evans DH, Pavord ID (2008) The Leicester Cough Monitor: preliminary validation of an automated cough detection system in chronic cough. Eur Respir J 31(5):1013–1018CrossRefPubMed
6.
Zurück zum Zitat Matos S, Birring SS, Pavord ID, Evans DH (2007) An automated system for 24-h monitoring of cough frequency: the leicester cough monitor. IEEE Trans Bio Med Eng 54(8):1472–1479CrossRef Matos S, Birring SS, Pavord ID, Evans DH (2007) An automated system for 24-h monitoring of cough frequency: the leicester cough monitor. IEEE Trans Bio Med Eng 54(8):1472–1479CrossRef
7.
8.
Zurück zum Zitat Birring SS, Parker D, Brightling CE, Bradding P, Wardlaw AJ, Pavord ID (2004) Induced sputum inflammatory mediator concentrations in chronic cough. Am J Respir Crit Care Med 169(1):15–19CrossRefPubMed Birring SS, Parker D, Brightling CE, Bradding P, Wardlaw AJ, Pavord ID (2004) Induced sputum inflammatory mediator concentrations in chronic cough. Am J Respir Crit Care Med 169(1):15–19CrossRefPubMed
9.
Zurück zum Zitat Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan MD, Pavord ID (2003) Development of a symptom specific health status measure for patients with chronic cough: leicester Cough Questionnaire (LCQ). Thorax 58(4):339–343CrossRefPubMedPubMedCentral Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan MD, Pavord ID (2003) Development of a symptom specific health status measure for patients with chronic cough: leicester Cough Questionnaire (LCQ). Thorax 58(4):339–343CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat French CT, Irwin RS, Fletcher KE, Adams TM (2002) Evaluation of a cough-specific quality-of-life questionnaire. Chest 121(4):1123–1131CrossRefPubMed French CT, Irwin RS, Fletcher KE, Adams TM (2002) Evaluation of a cough-specific quality-of-life questionnaire. Chest 121(4):1123–1131CrossRefPubMed
11.
Zurück zum Zitat Guidance for industry (2006) Patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 4:79CrossRef Guidance for industry (2006) Patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 4:79CrossRef
12.
Zurück zum Zitat Patrick DL, Burke LB, Powers JH et al (2007) Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health 10(Suppl 2):S125–S137CrossRefPubMed Patrick DL, Burke LB, Powers JH et al (2007) Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health 10(Suppl 2):S125–S137CrossRefPubMed
13.
Zurück zum Zitat Yousaf N, Monteiro W, Parker D, Matos S, Birring S, Pavord ID (2010) Long-term low-dose erythromycin in patients with unexplained chronic cough: a double-blind placebo controlled trial. Thorax 65(12):1107–1110CrossRefPubMed Yousaf N, Monteiro W, Parker D, Matos S, Birring S, Pavord ID (2010) Long-term low-dose erythromycin in patients with unexplained chronic cough: a double-blind placebo controlled trial. Thorax 65(12):1107–1110CrossRefPubMed
14.
Zurück zum Zitat Ryan NM, Birring SS, Gibson PG (2012) Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet 380(9853):1583–1589CrossRefPubMed Ryan NM, Birring SS, Gibson PG (2012) Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet 380(9853):1583–1589CrossRefPubMed
15.
Zurück zum Zitat Hunninghake GW, Costabel U, Ando M et al (1999) ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 16(2):149–173PubMed Hunninghake GW, Costabel U, Ando M et al (1999) ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 16(2):149–173PubMed
17.
Zurück zum Zitat Mana J, Gomez-Vaquero C, Montero A et al (1999) Lofgren’s syndrome revisited: a study of 186 patients. Am J Med 107(3):240–245CrossRefPubMed Mana J, Gomez-Vaquero C, Montero A et al (1999) Lofgren’s syndrome revisited: a study of 186 patients. Am J Med 107(3):240–245CrossRefPubMed
18.
Zurück zum Zitat Denny MC, Fotino AD (2013) The Heerfordt-Waldenstrom syndrome as an initial presentation of sarcoidosis. In: Proceedings (Baylor University. Medical Center. 26(4):390–392 Denny MC, Fotino AD (2013) The Heerfordt-Waldenstrom syndrome as an initial presentation of sarcoidosis. In: Proceedings (Baylor University. Medical Center. 26(4):390–392
19.
Zurück zum Zitat Scadding JG (1961) Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years’ observation. BMJ 2(5261):1165–1172CrossRefPubMedPubMedCentral Scadding JG (1961) Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years’ observation. BMJ 2(5261):1165–1172CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Judson MA, Costabel U, Drent M et al (2014) The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis 31(1):19–27PubMed Judson MA, Costabel U, Drent M et al (2014) The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis 31(1):19–27PubMed
21.
Zurück zum Zitat Smith JA, Kitt MM, Morice AH et al (2017) Mk-7264, a P2x3 receptor antagonist reduces cough frequency in patients with refractory cough: results from a randomized, controlled, phase 2b clinical trial (Abstract, American Thoracic Soceity Annual Meeting, May 22, 2017). Am J Respir Crit Care Med 195:A7608 Smith JA, Kitt MM, Morice AH et al (2017) Mk-7264, a P2x3 receptor antagonist reduces cough frequency in patients with refractory cough: results from a randomized, controlled, phase 2b clinical trial (Abstract, American Thoracic Soceity Annual Meeting, May 22, 2017). Am J Respir Crit Care Med 195:A7608
22.
Zurück zum Zitat Sinha A, Lee KK, Rafferty GF et al (2016) Predictors of objective cough frequency in pulmonary sarcoidosis. Eur Respir J 47(5):1461–1471CrossRefPubMed Sinha A, Lee KK, Rafferty GF et al (2016) Predictors of objective cough frequency in pulmonary sarcoidosis. Eur Respir J 47(5):1461–1471CrossRefPubMed
23.
Zurück zum Zitat Judson MA, Boan AD, Lackland DT (2012) The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis 29(2):119–127PubMed Judson MA, Boan AD, Lackland DT (2012) The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis 29(2):119–127PubMed
24.
Zurück zum Zitat Baughman RP, Teirstein AS, Judson MA et al (2001) Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 164(10 Pt 1):1885–1889CrossRefPubMed Baughman RP, Teirstein AS, Judson MA et al (2001) Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 164(10 Pt 1):1885–1889CrossRefPubMed
25.
Zurück zum Zitat Burke RR, Stone CH, Havstad S, Rybicki BA (2009) Racial differences in sarcoidosis granuloma density. Lung 187(1):1–7CrossRefPubMed Burke RR, Stone CH, Havstad S, Rybicki BA (2009) Racial differences in sarcoidosis granuloma density. Lung 187(1):1–7CrossRefPubMed
26.
Zurück zum Zitat Ungprasert P, Crowson CS, Matteson EL (2016) Influence of gender on epidemiology and clinical manifestations of sarcoidosis: A population-based retrospective cohort study 1976-2013. Lung. 195:87CrossRefPubMed Ungprasert P, Crowson CS, Matteson EL (2016) Influence of gender on epidemiology and clinical manifestations of sarcoidosis: A population-based retrospective cohort study 1976-2013. Lung. 195:87CrossRefPubMed
27.
Zurück zum Zitat Baughman RP, Drent M, Kavuru M et al (2006) Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174(7):795–802CrossRefPubMed Baughman RP, Drent M, Kavuru M et al (2006) Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174(7):795–802CrossRefPubMed
28.
Zurück zum Zitat Judson MA, Baughman RP, Costabel U et al (2014) Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J 44(5):1296–1307CrossRefPubMed Judson MA, Baughman RP, Costabel U et al (2014) Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J 44(5):1296–1307CrossRefPubMed
29.
Zurück zum Zitat Baughman RP, Drent M, Culver DA et al (2012) Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 29(2):90–98PubMed Baughman RP, Drent M, Culver DA et al (2012) Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 29(2):90–98PubMed
30.
31.
Zurück zum Zitat Jackson DM, Norris AA, Eady RP (1989) Nedocromil sodium and sensory nerves in the dog lung. Pulm Pharmacol 2(4):179–184CrossRefPubMed Jackson DM, Norris AA, Eady RP (1989) Nedocromil sodium and sensory nerves in the dog lung. Pulm Pharmacol 2(4):179–184CrossRefPubMed
32.
Zurück zum Zitat Tatar M, Sant’Ambrogio G, Sant’Ambrogio FB (1994) Laryngeal and tracheobronchial cough in anesthetized dogs. J Appl Physiol 76(6):2672–2679PubMed Tatar M, Sant’Ambrogio G, Sant’Ambrogio FB (1994) Laryngeal and tracheobronchial cough in anesthetized dogs. J Appl Physiol 76(6):2672–2679PubMed
33.
Zurück zum Zitat Lewis MM, Mortelliti MP, Yeager H Jr, Tsou E (2002) Clinical bronchiectasis complicating pulmonary sarcoidosis: case series of seven patients. Sarcoidosis Vasc Diffuse Lung Dis 19(2):154–159PubMed Lewis MM, Mortelliti MP, Yeager H Jr, Tsou E (2002) Clinical bronchiectasis complicating pulmonary sarcoidosis: case series of seven patients. Sarcoidosis Vasc Diffuse Lung Dis 19(2):154–159PubMed
34.
Zurück zum Zitat Laitinen LA, Haahtela T, Kava T, Laitinen A (1983) Non-specific bronchial reactivity and ultrastructure of the airway epithelium in patients with sarcoidosis and allergic alveolitis. Eur J Respir Dis Suppl 131:267–284PubMed Laitinen LA, Haahtela T, Kava T, Laitinen A (1983) Non-specific bronchial reactivity and ultrastructure of the airway epithelium in patients with sarcoidosis and allergic alveolitis. Eur J Respir Dis Suppl 131:267–284PubMed
35.
Zurück zum Zitat Marcias S, Ledda MA, Perra R, Severino C, Rosetti L (1994) Aspecific bronchial hyperreactivity in pulmonary sarcoidosis. Sarcoidosis 11(2):118–122PubMed Marcias S, Ledda MA, Perra R, Severino C, Rosetti L (1994) Aspecific bronchial hyperreactivity in pulmonary sarcoidosis. Sarcoidosis 11(2):118–122PubMed
36.
Zurück zum Zitat Ohrn MB, Skold CM, van Hage-Hamsten M, Sigurdardottir O, Zetterstrom O, Eklund A (1995) Sarcoidosis patients have bronchial hyperreactivity and signs of mast cell activation in their bronchoalveolar lavage. Respiration 62(3):136–142CrossRefPubMed Ohrn MB, Skold CM, van Hage-Hamsten M, Sigurdardottir O, Zetterstrom O, Eklund A (1995) Sarcoidosis patients have bronchial hyperreactivity and signs of mast cell activation in their bronchoalveolar lavage. Respiration 62(3):136–142CrossRefPubMed
37.
Zurück zum Zitat Rothman KJ (1990) No adjustments are needed for multiple comparisons. Epidemiology 1(1):43–46CrossRefPubMed Rothman KJ (1990) No adjustments are needed for multiple comparisons. Epidemiology 1(1):43–46CrossRefPubMed
38.
Zurück zum Zitat Saville DJ (1990) Multiple comparison procedures: the practical solution. Am Stat 44(2):174–180 Saville DJ (1990) Multiple comparison procedures: the practical solution. Am Stat 44(2):174–180
Metadaten
Titel
The Assessment of Cough in a Sarcoidosis Clinic Using a Validated instrument and a Visual Analog Scale
verfasst von
Marc A. Judson
Amit Chopra
Edward Conuel
Efstratios Koutroumpakis
Christopher Schafer
Adam Austin
Robert Zhang
Kerry Cao
Rani Berry
Malik M. H. S. Khan
Aakash Modi
Ritu Modi
Stephanie Jou
Furqan Ilyas
Recai M. Yucel
Publikationsdatum
13.07.2017
Verlag
Springer US
Erschienen in
Lung / Ausgabe 5/2017
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-017-0040-3

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Dänische Zwillingsstudie deutet auf erhöhtes Krebsrisiko bei Tätowierten hin

Haben Tattoo-Träger und -Trägerinnen ein erhöhtes Risiko, an Hautkrebs oder einem Lymphom zu erkranken? Die Ergebnisse einer Zwillingsstudie aus Dänemark scheinen dafür zu sprechen. Die Forschungsgruppe rät vorerst zur Zurückhaltung beim Tätowieren.

Automatisierte Insulinabgabe auch bei Typ-2-Diabetes von Vorteil?

Ergebnisse der 2IQP-Studie legen nahe, dass eine automatisierte Insulinabgabe (AID) auch bei Menschen mit Typ-2-Diabetes eine strengere Kontrolle des Langzeitblutzuckers erlaubt. Allerdings bleiben Fragen offen

Osteoporose-Indizes offenbar wenig sinnvoll bei jüngeren Frauen

In einer US-Studie war keiner von drei getesteten Osteoporose-Indizes verlässlich genug, um bei postmenopausalen Frauen unter 65 Jahren ein klinisch relevantes Frakturrisiko zu erkennen.

Schützt kutane Autoimmunität vor Hauttumoren?

Schwedische Registerdaten deuten auf ein geringeres Risiko für bestimmte Hauttumoren bei Personen mit Vitiligo oder autoimmuner Alopezie. Wie es dazu kommt, ist dagegen unklar.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.